Our Team
At D4 Bioventures, we are not just consultants but seasoned practitioners with a legacy of hands-on experience. Steven, David, Andrew and Jeremy bring a unique mix of multi-disciplinary expertise and practical know-how rarely available to Medical Research Institutes (MRIs) and Startups. Each team member honed their skills over years of active participation in their respective fields, from corporate law to venture capital and life science technology commercialisation. Our team's deep-seated knowledge comes from being at the frontline, ensuring that our clients benefit from our capabilities and the genuine partnership we offer. Collaborating with D4 Bioventures means embarking on a journey with experts as dedicated to your success as they are a pleasure to work with.
Andrew Silberberg
Andrew Silberberg is a Sydney-based investor, advisor and company director. From 2008 to 2015, he spent eight years as a partner and head of corporate in the Sydney office of Arnold Bloch Leibler, prior to which he worked at Freehills and Clifford Chance.
During that time, Andrew worked across various industries, including energy, financial services, property, health care and FMCG.
Since 2016, Andrew has been involved in investing in, managing and advising early-stage and other businesses. Andrew's experience includes leading cross-border transactions, structuring, raising equity and debt capital in Australia and the U.S., and negotiating strategic alliances, licenses and joint ventures.
Currently based in Sydney, Andrew has worked in the United States, United Kingdom and Switzerland.
Andrew is an alumnus of Monash University and the London School of Economics. Andrew sits on the boards and advisory boards of businesses and several community organisations.
David Barda
David is an entrepreneur, executive and advisor specialising in technology commercialisation and early stage ventures for biomedical technologies.
David was formerly, the Director for Business Development and Innovation at the Garvan Institute of Medical Research, one of Australia’s premier medical research institutes that performs ground breaking research in the areas of genomics, bioinformatics, cancer, and immunology.
He joined Garvan following a successful tenure in Singapore where he led a team commercialising medical technologies with A*STAR, the national science and technology agency, spinning off more than 15 life science ventures.
Highlights of his career have also included the spinning out from NICTA of Saluda Medical that now produce the “Evoke” spinal cord stimulator comprising closed loop feedback control for the treatment of chronic pain; and advisory roles with Anatomics a medical device company developing software for producing 3D printed patient specific implants; and with Clarity Pharmaceuticals, the Australian listed biotech that is developing a pipeline of radiopharmaceuticals and theranostics using Copper 64 and Copper 66 radioisotopes.
David was also a founder of Simavita, the developer of a smart nappy, that in 2005 was one of the first approved medical devices in Australia to incorporate AI.
David has a First-class Honours degree in Computer Science from UNSW, a Masters of Intellectual Property Law from Monash University and is an inventor on 30 granted patents. His passion for science and commercialisation has led him to delve deeper in fields such as business models for precision medicine, AI in healthcare, genomics and bioinformatics, medical IOT, neurotechnology, bioelectronic medicine, medical imaging and wearable sensors. In parallel to his role at D4, David is currently also founding executive director for Sequins Standards Inc, a Garvan Institute of Medical Research spin-off.
Jeremy Waine
Jeremy is an investment banking, corporate finance and financial services professional with over 25 years of experience with leading Australian and international companies.
He began his career as a corporate lawyer at King & Wood Mallesons. Then he moved into investment banking, principal acquisitions and investment management with UBS Investment Bank, CBA, Westpac and GE Capital.
In these roles, Jeremy advised some of Australia’s largest corporations on equity capital markets, acquisition financing, corporate structuring and M&A.
Jeremy also recently served as the Chief Investment Officer of Bickham Court Group, a Sydney-based single-family office.
Jeremy is a Board Member and Treasurer of the Children’s Medical Research Institute, an internationally recognised medical research institution. He is Chairman of the Institute’s Finance & Investment Committee (which is responsible for managing a large endowment fund) and a member of the Audit & Risk Committee. Jeremy was a member of the archTIS Advisory Group and is on the Advisory Board of Sinorbis, Lifesherpa and Neeon, and a member of the Investment Committee of the NRL Players Association.
Jeremy was a member of the Board of The Montefiore Home from 2008 until 2017, served on the Finance & Investment Committee, and was Chair of the Nominations Committee.
Jeremy holds a Bachelor of Commerce and Law (UNSW) and a Graduate Diploma in Applied Finance and Investment (Securities Institute Australia). He has also completed the Massachusetts Institute of Technology Global Entrepreneurship Program in Boston and advanced management training at the AGSM.
Steven Suchting
Dr Steven Suchting is an accomplished professional with a global track record in developing and commercialising early-stage biomedical technologies. His extensive career encompasses venture capital, startup executive management, business development, and technology transfer.
As a former Investment Director for venture capital firm IP Group Australia, Steven was responsible for identifying opportunities across the Group of Eight (Go8) Universities and led seed and Series A investments into multiple life science spin-out companies.
Previously, Steven managed both in- and out-licensing activities and strategic partnerships at LifeArc, a drug development organisation based in London. Currently, in parallel to his role in D4 Bioventures, Steven is CEO of a University of New South Wales spin-out company developing small molecule therapeutics for pain indications, and he was previously COO of a University of Queensland spin-out developing a biologic drug for non-alcoholic steatohepatitis.
Steven also has extensive experience in technology transfer, having led the Life Sciences Division at the National University of Singapore’s Industry Liaison Office and commercialising Life Science Technologies at Cambridge Enterprise, the technology transfer arm of the University of Cambridge. Over the course of his career, Steven has negotiated over 30 commercial deals with major pharmaceutical companies, venture-backed spin-outs, and device manufacturers. He has also sat on the boards of several Life Science Companies.
A Rhodes Scholar, Steven earned a DPhil in Clinical Medicine from the University of Oxford and completed postdoctoral research at the Collège de France in Paris. He holds a Bachelor of Science with First-class Honours and a Bachelor of Arts degree from the University of Queensland.